Literature DB >> 1431095

Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens.

J Dhein1, P T Daniel, B C Trauth, A Oehm, P Möller, P H Krammer.   

Abstract

Apoptosis, programmed cell death, was previously shown to be induced by the mAb anti-APO-1 (IgG3, kappa) by binding to the APO-1 cell surface Ag, a new member of the nerve growth factor/TNF receptor superfamily. To investigate the role of the Ig H chain Fc regions we compared induction of apoptosis by the original mAb IgG3 anti-APO-1 with anti-APO-1 F(ab')2 fragments and different anti-APO-1 isotypes (IgG1, IgG2b, IgG2a, and IgA) isolated by sequential sublining. We found that IgG3 was the most active isotype; IgG1, IgG2a, and IgA showed intermediate activity, and IgG2b and F(ab')2 were inactive. Cytotoxic activity of the inactive or less active antibody preparations was fully reconstituted by protein A, anti-mouse Ig, or anti-mouse Ig F(ab')2, respectively. Thus, APO-1-mediated induction of apoptosis was dependent on efficient cross-linking of APO-1 cell surface Ag, indirectly augmented by anti-APO-1 Fc-Fc self-aggregation. Because of their different in vitro activity we selected IgG3-, IgG2b-, and IgA anti-APO-1 to test their antitumor activity against solid human B lymphoblastoid tumors in SCID mice. The isotypes showed a different serum half-life (IgG3: 9.2-10.4 days, IgG2b: 1.9-2.6 days, and IgA: 14.1-29.2 h) and a different initial tumor localization 4 h after i.p. injection (IgG3 around the blood vessels, IgG2b homogeneously, and IgA heterogeneously distributed in the tumor). All antibody preparations induced tumor regression by induction of apoptosis, even IgG2b anti-APO-1 inactive in vitro without cross-linking. The activity of IgA anti-APO-1, which did not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity indicates that apoptosis may be used as the main if not the only mechanism of induction of tumor regression in vivo. As with in vitro, IgG3 anti-APO-1 was the most effective isotype also in vivo. This result suggests that cross-linking of APO-1 on the tumor cell surface may also be required for tumor regression by apoptosis in vivo. Taken together, our data show that selective targeting of apoptosis to tumors may be an efficient antitumor mechanism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1431095

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  Cartilage-hair hypoplasia syndrome: increased apoptosis of T lymphocytes is associated with altered expression of Fas (CD95), FasL (CD95L), IAP, Bax, and Bcl2.

Authors:  L Yel; S Aggarwal; S Gupta
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

2.  Activation of distinct caspase-like proteases by Fas and reaper in Drosophila cells.

Authors:  T Kondo; T Yokokura; S Nagata
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

3.  Role of Ced-3/ICE-family proteases in staurosporine-induced programmed cell death.

Authors:  M D Jacobsen; M Weil; M C Raff
Journal:  J Cell Biol       Date:  1996-06       Impact factor: 10.539

Review 4.  The role of Fas-FasL in CD8+ T-cell-mediated insulin-dependent diabetes mellitus (IDDM).

Authors:  H T Kreuwel; L A Sherman
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

5.  The role of receptor internalization in CD95 signaling.

Authors:  Kyeong-Hee Lee; Christine Feig; Vladimir Tchikov; Robert Schickel; Cora Hallas; Stefan Schütze; Marcus E Peter; Andrew C Chan
Journal:  EMBO J       Date:  2006-02-23       Impact factor: 11.598

6.  TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.

Authors:  Johannes Lemke; Andreas Noack; Dieter Adam; Vladimir Tchikov; Uwe Bertsch; Christian Röder; Stefan Schütze; Harald Wajant; Holger Kalthoff; Anna Trauzold
Journal:  J Mol Med (Berl)       Date:  2010-03-31       Impact factor: 4.599

Review 7.  Looking beneath the surface: the cell death pathway of Fas/APO-1 (CD95).

Authors:  B Z Stanger
Journal:  Mol Med       Date:  1996-01       Impact factor: 6.354

Review 8.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

9.  Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.

Authors:  Steffen Salzmann; Axel Seher; Johannes Trebing; Daniela Weisenberger; Alevtina Rosenthal; Daniela Siegmund; Harald Wajant
Journal:  J Biol Chem       Date:  2013-03-26       Impact factor: 5.157

10.  Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice.

Authors:  R C Bargou; C Wagener; K Bommert; M Y Mapara; P T Daniel; W Arnold; M Dietel; H Guski; A Feller; H D Royer; B Dörken
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.